HIF-PH inhibitor for renal anemia with chronic heart failure: A prospective observation study

HIF-PH inhibitor for renal anemia with chronic heart failure: A prospective observation study - HIF-PH inhibitor for renal anemia with chronic heart failure: A prospective observation study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041651

Enrollment

Registered

2020-09-02

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia with chronic heart failure using CERA

Interventions

Roxadustat, Daprodustat, Vadadustat, Moridustat randomly assign Observation for 6 months Roxadustat, Daprodustat, Vadadustat, Moridustat randomly assign Observation for 6 months Roxadustat, Daprodus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal anemia with chronic heart failure using CERA

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
Hb	—

Secondary

Measure	Time frame
1)NTProBNP 2) Cr, eGFR 3)EPO 4) Fe, UIBC, Ferritin 5)T3,T4,TSH 6) side effect	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026